Though animal models support the potential for senolytics and Tert expression in the regulation of aging-associated senescence, clinical studies will be necessary to determine whether such approaches are also effective in delaying senescence-associated metabolic disease in humans. This evidence concerns the gene TERT and metabolic disease.